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Summary As part of an 'enzyme-directed' approach to bioreductive drug development, we have measured the
activity of NADH:cytochrome b5 reductase (B5R) in human cancer cell lines in order to assess the role of this
enzyme in activating bioreductive drugs, and thus in influencing the cytotoxicity of these compounds. At
present, there is no validated assay reported in the literature for measuring the activity of B5R in tumour cells,
and current measurements have assumed that the enzyme activity can be measured either as the NADH-
dependent reduction ofcytochrome c or as the non-dicoumarol-inhibitable activity in the DT-diaphorase assay.
Using p-hydroxymercuribenzoate (pHMB) as an inhibitor of B5R, we have quantified the contribution of B5R
to the NADH-dependent reduction of cytochrome c and to the overall reduction of cytochrome c in the DT-
diaphorase assay. In the former we found that residual uninhibited activity remained in the presence ofpHMB,
in some cases accounting for up to 60% of the total reduction of cytochrome c. Thus, simply measuring the
NADH-dependent reduction of cytochrome c consistently overestimated B5R activity. We also found that the
non-dicoumarol-inhibitable activity in the DT-diaphorase assay underestimated B5R activity, especially in cell
lines with high DT-diaphorase activity. Therefore, we have developed a spectrophotometric assay for
measuring B5R activity as the pHMB-inhibitable NADH-dependent reduction of cytochrome c. This has been
used to measure the B5R activity of a panel of 22 human tumour cell lines, in which we found 7-fold and 3-
fold variations in activity expressed per cell or per mg protein respectively.
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Cytochrome b5 reductase (NADH:cytochrome b5 reductase;
EC 1.6.2.2) is FAD-containing flavoprotein. The enzyme is
usually bound to the endoplasmic reticulum, but has also
been found bound to outer mitochondrial membranes in the
liver (Sottocasa et al., 1967) and plasma membranes in
erythrocytes (Choury et al., 1981). In addition, an
immunologically related soluble form of the enzyme has
been purified from erythrocyte cytosol (Passon et al., 1972;
Leroux et al., 1977) and from rabit liver cytosol (Lostanlen et
al., 1987). Cytochrome b5 reductase transfers reducing
equivalents from NADH to cytochrome b5 in the endoplas-
mic reticulum, which, in turn, donates electrons to a variety
of electron acceptors, which include fatty acid desaturases,
elongase, cytochrome P450, methaemoglobin and metmyo-
globin (Ghesquier et al., 1985; Guiray and Arinc, 1991).
Cytochrome b5 reductase is potentially an important
enzyme required for the reductive activation of bioreductive
drugs that can be used in the treatment of solid tumours.
These drugs are targeted specifically at the radiation-
insensitive population of cells residing in hypoxic regions of
tumours, where they are activated by cellular reductases
generally only under conditions of low oxygen tension. In
vitro studies have indicated that purified cytochrome b5
reductase is able to activate mitomycin C (Hodnick and
Sartorelli, 1993), although its role in the whole cell is unclear.
We have recently shown that microsomal cytochrome b5
reductase is intimately involved in the activation of the fused
pyrazaine mono-N-oxide bioreductive drug, RB90740
(Barham and Stratford, 1996). We, therefore, wanted to
extend this study by characterising the expression and activity
of this enzyme in a large panel of human cancer cell lines.
This would enable the suitability of RB90740 as a candidate
for the 'enzyme-directed' approach to bioreductive drug
development (Workman and Walton, 1989; Workman and
Stratford, 1993) to be assessed. This requires knowledge not
only of the enzymology of drug activation, but also of the
level of activity of appropriate enzymes in different tumour
types. Thus, in theory a bioreductive drug can be targeted at
a particular tumour type according to its enzyme profile.
Cytochrome b5 reductase has not been widely studied as a
bioreductive enzyme, and there is no simple assay for
measuring its activity in tumour cells. The activity of the
purified enzyme is usually measured using cytochrome b5 as
substrate (Tamura et al., 1988; Guiray and Arinc, 1991).
However, cytochrome b5 is not available commercially, and,
therefore, must be purified from liver. The activities of other
reductase enzymes such as NADPH: cytochrome P450
reductase or DT-diaphorase, both of which are important for
the activation of bioreductive drugs, can be measured
spectrophotometrically as the reduction of the artificial
electron acceptor cytochrome c. DT-diaphorase activity is
determined spectrophotometrically as the dicoumarol-inhibi-
table, NADH-dependent reduction of cytochrome c in the
presence of menadione (Robertson et al., 1994). The basis of
the DT-diaphorase assay is depicted in Figure 1. DT-
diaphorase does not reduce cytochrome c directly. Menadione
is a substrate of DT-diaphorase, which reduces it to the
hydroquinone, and this product subsequently reduces cyto-
chrome cnon-enzymatically. The reduction ofmenadione is the
rate-limiting step in this reaction. Hence, by measuring the rate
of reduction of cytochrome c, a measure of DT-diaphorase
activity is obtained. However, other enzymes, including
cytochrome b5 reductase, are able to reduce cytochrome c
directly. Thus, using this method, the total reduction of
cytochrome c measured spectrophotometrically comprises
both the indirect reduction by DT-diaphorase and the direct
reduction by cytochrome b5 reductase (and possibly by other
reductase enzymes). The contribution ofDT-diaphorase to the
overall reduction of cytochrome c is quantified by adding
dicoumarol, an inhibitor of this enzyme. To date, it has been
assumed that either the non-dicoumarol-inhibitable reduction
of cytochrome c (i.e. the residual activity observed in the
presence of dicoumarol) (Segura-Aguilar et al., 1990) or the
NADH-dependent reduction of cytochrome c (i.e. in the
absence of menadione) (Plumb et al., 1994) are equivalent to
cytochrome b5 reductase activity. However, neither of these
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et al., 1994). All cell lines were maintained in exponential
growth phase in RPMI medium supplemented with 0.8%
(w/v) glutamine (final concentration 2 mM) and 10% (v/v)
FCS. Exceptions were SkBr3 and MCF-7 (Lp) cells, which
were maintained in Dulbecco's modified Eagle medium
(DMEM) E4 medium, and SK-MES, LDAN and CALU-3
cells, which were maintained in a 50: 50 mixture of DMEM
E4 and Ham's F1O.
Figure 1 A schematic representation of the DT-diaphorase
assay. DT-diaphorase cannot reduce cytochrome c directly, but
reduces menadione to a hydroquinone, which in turn chemically
reduces the cytochrome c. In addition, cytochrome c is reduced
directly by cytochrome b5 reductase, and possible by other
enzymes, depicted by '?'. In order to quantify the contribution of
DT-diaphorase to the total reduction of cytochrome c,
dicoumarol is added, which is a selective inhibitor of this
enzyme. Thus, the DT diaphorase activity can be measured as
either the dicoumarol-inhibitable or the menadione-dependent
activity, and the remaining activity as the menadione independent
or dicoumarol non-inhibitable. In order to distinguish cytochrome
b5 reductase from other reductases, pHMB is added, a reportedly
selective inhibitor of this enzyme. Thus, DT-diaphorase activity
may also be measured as pHMB non-inhibitable, and cytochrome
b5 reductase activity as pHMB inhibitable. The actual equivalence
of these methods is shown in Figure 2 and discussed in the
Results section.
methods appears to have been validated. In particular, the
possible existence ofother reductases, which may contribute to
the overall reduction ofcytochrome c, has not been addressed.
In the present study we have investigated whether the two
methods assumed to be measures of cytochrome b5 reductase
activity are equivalent and valid measurements. In addition, we
have used p-hydroxymercuribenzoate (pHMB), a selective
inhibitor of cytochrome b5 reductase (Lostanlen et al., 1987),
to quantify the contribution ofthis enzyme to the total NADH-
dependent reduction of cytochrome c. The activity of
cytochrome b5 reductase in a panel of 22 human tumour cell
lines has then been measured using the assay described here,
with a view to defining the role ofthis enzyme in the activation
and toxicity of RB90740 and other bioreductive drugs.
Materials and methods
Tissue culture media were obtained from ICRF (Clair Hall
Laboratories, UK). Fetal calf serum (FCS), NADH (,B-
NADH, disodium salt), cytochrome c (from horse heart)
pHMB (p-hydroxymercuribenzoic acid, sodium salt) dicou-
marol (3,3'-methylene-bis(4-hydroxy-coumarin) and mena-
dione were purchased from Sigma Chemical Co. (Poole,
UK). All other reagents were of analytical grade and were
purchased from BDH Ltd (Poole, UK).
Microsomes
Livers were obtained from female C3H mice and stored in
liquid nitrogen until use. Microsomes were prepared by
differential centrifugation using the method described by
Barham (1993). Microsomal pellets were resuspended in
0.25 M potassium phosphate buffer (pH 7.25) containing
30% glycerol (v/v) and stored as aliquots in liquid nitrogen.
Microsomal protein concentration was measured by the
Pierce BCA assay (Smith et al., 1985) using bovine serum
albumin (BSA) as the standard.
Cells and culture
SK-MES, LDAN, CALU-3 and H69 cell lines were gifts
from Dr Jane Plumb (CRC Beatson Laboratories, Glasgow,
UK). All other cell lines were from MRC stocks (Houlbrook
Preparation of cell lysates
Lysates were prepared from the pooled contents of two
25 cm2 flasks. Cells in exponential growth phase were washed
once with phosphate-buffered saline (PBS) and harvested by
the addition of 5 ml trypsin to each flask. The contents of the
two flasks were then pooled and centrifuged at 800 r.p.m. for
8 min. The cell pellet was washed in ice-cold PBS (pH 7.1)
and then resuspended in 2 ml Nuclear buffer A (10 mM
HEPES/potassium hydroxide, pH 7.4, 1.5 mM magnesium
chloride, 10 mm potassium chloride, 0.05 mM DTT) and
allowed to stand at 4°C for 10 min. Haemocytometer counts
of cell numbers were performed during this interval. The
suspensions were then sonicated using an MSE Soniprep 150
for 3 x 5 s at a nominal frequency of 23 kHz and an
oscillation amplitude of between 5 and 10 Mm. Samples
were placed on ice between each sonication. The suspensions
were then allowed to stand on ice for a further 10 min, and
then centrifuged at 12 000 r.p.m. (7800 g) for 15 min at 4°C.
The resulting lysate was removed and stored in liquid
nitrogen until required. The protein concentration of the
lysates was determined using the Pierce protein assay (Smith
et al., 1985) using BSA as the standard.
Cytochrome b5 reductase assay
The cytochrome b5 reductase activity ofthe tumour cell lysates
was determined spectrophotometrically as the pHMB-inhibi-
table, NADH-dependent reduction ofcytochrome c. Develop-
ment of the assay, and rationale for this method are described
in the Results section. The final assay protocol is described
here.
Lysates were thawed rapidly at 37°C immediately before use
and maintained on ice. An assay mixture comprising 900 ,UM
NADH and 70 gM cytochrome c in assay buffer (0.05 M
phosphate buffer, pH 6.8, prepared by mixing 0.05 M solutions
of potassium hydrogen phosphate and potassium dihydrogen
phosphate to achieve pH 6.8) was prepared immediately before
use by adding 2 ml of a 10 mm stock solution of NADH and
2.8 ml of a 1 mM stock solution ofcytochrome c to 35.2 ml of
assay buffer. The mixture was wrapped in aluminium foil to
prevent light degradation and kept at 37°C. The pHMB was
prepared as an 8 mM stock solution in assay buffer containing
20 p1 sodium hydroxide (2 M) per ml buffer. The addition of
25 p1 ofthis solution to the 1 ml incubation volume achieved a
final concentration of0.2 mM pHMB.
To measure the cytochrome b5 reductase activity of each
lysate, paired samples were prepared which contained 1 ml of
the assay mixture, 25 Ml of either pHMB or assay buffer and
20 p1 of lysate. The change of absorbance at 550 nm was
followed for 1 min. If the rate of change of absorbance was
outside the range 0.05 to 0.15 dA min-', the incubation was
repeated, modifying the volume of lysate added to the
incubation accordingly. In each case it was ensured that the
rate of change of absorbance was proportional to the amount
of protein added. Initial rates of reaction were calculated
based on an extinction coefficient of 2 1 mm-' cm-1
(Williams and Kamin, 1962) and expressed as either nmol
cytochrome c reduced per minute per mg of protein or per
106 cells. The pHMB-inhibitable activity was calculated as the
difference between the activity of the two cuvettes. The
cytochrome b5 reductase activity of each lysate was measured
in triplicate. Three lysates from each cell line were assayed.
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Results
Optimisation of assay conditions
Initial experiments to optimise the assay conditions were
performed using mouse liver microsomes, which contain only
membrane-bound enzymes, and therefore do not include DT-
diaphorase, which is a cytosolic enzyme. Initially, we
measured cytochrome b5 reductase as the NADH-dependent
reduction of cytochrome c. We have measured this activity in
a number of buffers with differing pHs and phosphate
concentrations, since it has been shown that the activities of
different reductase enzymes have differing optima with
respect to both buffer phosphate concentrations and pH.
For example, NADPH:P450 reductase activity is measured at
a phosphate concentration of 0.2 M and pH 7.6 (Patterson et
al., 1995), whereas DT-diaphorase activity is often measured
in PBS (0.01 M phosphate, pH 7.4) (Robertson et al., 1994),
although Ernster et al. (1962) found the phosphate
concentration to be optimal at 0.05 M. Figure 2 shows that
the NADH-dependent reduction of cytochrome c was slower
at low and high phosphate concentrations, and was optimal
at 0.05 M phosphate, at all pHs tested.
The activity of cytochrome b5 reductase has been reported
to be dependent on pH. Thus, the ability of purified
cytochrome b5 reductase to reduce mitomycin C is greater
at pH 6.6 than at pH 7.6 (Hodnick and Sartorelli, 1993).
Similarly, cytochrome b5 reductase was found to reduce
doxorubicin at pH 6.6, but was unable to catalyse this
reduction at pH 7.6 (Hodnick and Sartorelli, 1994). From
Figure 2 it can be seen that the pH dependence of the
reduction of cytochrome c by cytochrome b5 reductase was
fairly broad and was optimal at pH 6.8. This is in agreement
with Guray and Arinc (1991) who showed that the activity of
the enzyme purified from sheep lung, measured as the
reduction of ferricyanide or partially purified cytochrome b5
as the electron acceptor, was optimal at pH 6.8.
The rate of NADH-dependent reduction of cytochrome c
was found to be proportional to cytochrome c concentration
in the range of 3-8 gM (data not shown). Thus, the
concentration of 70 /uM used in the assay routinely (taken
from the DT-diaphorase assay) was considerably in excess.
We confirmed that this substrate concentration was not rate
limiting, and nor did it have an inhibitory effect on the
enzyme activity. Similarly, the 900 iuM NADH concentration
from the DT-diaphorase assay was also shown to be neither
rate limiting nor inhibitory.
The NADPH:P450 reductase assay, measured spectro-
photometrically as the NADPH-dependent reduction of
cytochrome c, requires the presence of KCN (10 gM) to
inhibit any possible reduction of cytochrome c by mitochon-
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drial electron transfer enzymes (Phillips and Langdon, 1962).
We found that this concentration of KCN only slightly
inhibited the NADH-dependent reduction of cytochrome c in
mouse liver microsomes, and did not inhibit this activity in
cell lysates. Therefore, we did not include KCN in our
cytochrome b5 reductase assay. Furthermore, KCN was
found to prevent the inhibition of this enzyme by pHMB
(data not shown).
Defining the best measure of cytochrome b5 reductase activity
The equivalence of the three possible methods for measuring
cytochrome b5 reductase activity [i.e. NADH-dependent
(menadione-independent), dicoumarol non-inhibitable, and
the pHMB-inhibitable reduction of cytochrome c] was
assessed in three different human tumour cell lines with
high, intermediate and low DT-diaphorase activities: H460,
T47D and ZR75 lines, respectively, and is shown in Figure 3.
Considering DT-diaphorase activity first (Figure 3a), it can
be seen that in each of the cell lines the dicoumarol-
inhibitable and menadione-dependent activities are virtually
identical. However, the pHMB non-inhibitable activity
consistently underestimated the DT-diaphorase activity. This
phenomenon appears to be more marked in the cell lines with
the higher DT-diaphorase activity. The most likely explana-
tion for this apparent underestimation of DT-diaphorase
activity is that pHMB also inhibits DT-diaphorase. This is
confirmed by the fact that a 200 gM concentration ofpHMB
inhibits purified human DT-diaphorase by approximately
35% (data not shown). However, this apparent lack of
selectivity of pHMB is not a problem in the cytochrome b5
reductase assay described here because the assay does not
incorporate menadione, so that DT-diaphorase makes no
contribution to the overall rate of cytochrome c reduction.
However, it does mean that different assays are needed for
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Figure 2 Importance of buffer phosphate concentration and pH
on the activity of cytochrome b5 reductase in mouse liver
microsomes.
Figure 3 Comparison of each of the methods proposed to be
measures of DT-diaphorase activity (a) and cytochrome b5
reductase activity (b) in three human tumour cell lines.
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determining the activities of the two enzymes, and that these
values cannot be derived simultaneously from a single assay.
With respect to the measurement of cytochrome b5
reductase activity, Figure 3b shows the results of the three
methods in the three cell lines. In the T47D cell line, which
has low DT-diaphorase activity, the three methods give
equivalent measures of cytochrome b5 reductase activity.
However, in the two high DT-diaphorase activity cell lines,
the dicoumarol non-inhibitable activity is a considerable
underestimation of cytochrome b5 reductase activity when
compared with the other two methods. In each case, the
menadione-independent activity, i.e. the NADH-dependent
reduction of cytochrome c, is higher than the pHMB-
inhibitable activity. This indicates that the former over-
estimates cytochrome b5 reductase activity, possibly owing to
the presence of other reductase enzymes that can also reduce
cytochrome c directly. The maximum inhibitory concentra-
tion of pHMB was 0.2 mM in all three cell lines. Increasing
the concentration of pHMB above this did not inhibit
cytochrome c reduction any further. However, the propor-
tion of cytochrome c reduction that was inhibited varied
between the cell lines. For example, 90% of the cytochrome c
reduction could be inhibited in the T47D cell line, whereas
only 60% of activity could be inhibited in the ZR75 cell line.
Thus, the contribution of enzymes other than cytochrome b5
reductase to the overall reduction of cytochrome c varies
between the lines. For this reason, pHMB-inhibitable activity
was considered to be the more accurate measure of
cytochrome b5 reductase activity.
Assay reproducibility
The inter- and intra-assay variation was measured in two cell
lines, ZR75 and H460. The cytochrome b5 reductase activity
was measured six times for each cell line giving the following
values: ZR75, 109.0+2.4; H460, 38.0+3.1 nmol cytochrome
c reduced min-m mg-' protein, mean+s.d. This is equivalent
to coefficients of variation of 2.2% and 8.2%, respectively,
for intra-assay variation. Enzyme activities were also
measured on three separate occasions, giving values of
106.1+4.6 (ZR75) and 43.6+2.6 (H460) nmol cytochrome
c reduced min-m mg-' protein. Thus, the coefficients of
variation for interassay variation were 4.3% and 6%
respectively. The lower limit of detection of the assay was
equivalent to a rate of change of absorbance of
0.005 dA min-'.
Cytochrome b, reductase activity in a panel of human tumour
cell lines
The cytochrome b5 reductase activities of lysates prepared
from the panel of human tumour cell lines are shown in
Table I. Values have been expressed both per mg of lysate
protein and per million cells. The values expressed per mg of
protein vary from 35.94+4.58 (LDAN) to 108.81 + 10.75
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Figure 4 The relative proportions ofpHMB-inhibitable and non-
inhibitable reduction of cytochrome c in the panel of human
tumour cell lines. pHMB-inhibitable activity is the cytochrome b5
reductase activity.
Table 1 Values of cytochrome b5 reductase (pHMB inhibitable) and pHMB non-inhibitable activities in a panel of human tumour cell lines
Cytochrome b5 reductase pHMB non-inhibitable Cytochrome b5 reductase pHMB non-inhibitable
activity activity activity activity
Tissue of (nmol cyt c reduced (nmol cyt c reduced (nmol cyt c reduced (nmol cyt c reduced
Cell line origin min-m mg 'protein) min-'mg-protein) min-'lecells) min-m 10 cells)
HBL-100 Breast 101.78±10.24 12.44+6.21 16.35± 3.56 1.95+ 1.00
MCF-7 (Nc) Breast 54.92+ 1.55 27.91 ±29.92 10.39±2.34 4.39+3.67
MCF-7 (Lp) Breast 61.33±3.56 6.57+5.56 12.56+ 1.23 1.36+ 1.13
MDA-231 Breast 49.80+3.04 3.82+3.86 8.07± 1.61 0.6±0.6
MDA-468 Breast 38.91 ± 8.33 12.59 ±7.61 6.70+ 1.74 2.16 + 1.32
SKBR3 Breast 59.74±7.27 16.64± 12.74 13.15±0.81 3.80±3.03
T47D Breast 50.37+ 6.46 3.92 +0.20 6.20 ± 1.20 0.48 ±0.05
ZR75 Breast 108.81+ 10.75 59.44+72.30 14.09+ 1.55 7.47+8.88
H226 NSCLC 81.51 +4.79 10.74+2.73 13.14+4.40 1.83+ 1.02
A549 NSCLC 51.64 +3.38 16.64+5.91 8.05 +2.97 2.42±0.45
H322 NSCLC 60.74+24.16 17.19+4.15 9.05 2.79 2.64+0.84
H358 NSCLC 39.00+7.20 7.72+6.47 7.46+ 1.74 1.44+1.12
H460 NSCLC 38.74+4.68 15.55+6.46 6.52 2.01 2.45+0.72
H522 NSCLC 78.43+ 1.55 10.50+6.97 10.22+ 1.71 1.43+ 1.14
H647 NSCLC 49.70+5.04 18.17+4.4 8 8.41 1.59 3.17+ 1.43
LDAN NSCLC 35.94+4.58 10.05±2.93 6.88+0.75 1.96+0.68
SKMES NSCLC 37.05 ± 12.02 16.25 ± 5.80 7.01 ± 1.87 3.18 ± 1.35
CALU-3 NSCLC 83.02+ 7.57 5.11 ±4.79 27.19+ 5.53 1.61 ± 1.39
H249 SCLC 92.23+ 15.93 12.33±3.21 8.37+ 1.44 1.13±0.34
H841 SCLC 71.34±2.67 13.16±7.56 11.13± 1.35 2.00±0.99
H69 SCLC 60.95 ±3.88 12.60±4.49 3.91 + 3.20 0.74+0.61
HT-1080 Fibrosarcoma 60.61 ± 7.85 8.87±5.64 15.95±4.14 2.18± 1.25
Values are mean± s.d. ofdeterminations from three lysates ofeach cell line. Values are expressed both per mg protein and per 106cells.
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(ZR75) nmol cytochrome c reduced min-' mg-' protein, a 3-
fold difference. When expressed per million cells, the enzyme
activity varies 6-fold, ranging from 3.91 +3.2 (H69)
to 27.19+5.53 (CALU-3) nmol cytochrome c reduced
min-' 10o6 cells.
Values for the pHMB non-inhibitable activity, i.e. the
residual activity in the presence of pHMB, in the cell lysates
are also shown in Table I, and the relative proportions of the
pHMB-inhibitable and non-inhibitable activities shown in
Figure 4. The values for non-inhibitable activity ranged from
approximately 4 (MDA-231, T47D) to 60 (ZR75) nmol
cytochrome c reduced min-' mg-' protein and represented
up to about 40% of the total reduction of cytochrome c. In
some cases cytochrome b5 reductase activity accounted for
nearly all of the NADH-dependent reduction of cytochrome
c, leaving a residual activity that was close to the limit of
detection of the assay.
Discussion
The 'enzyme-directed' approach to bioreductive drug de-
velopment (Workman and Walton, 1989; Workman and
Stratford, 1993) is based on variation in the ability of
different tumour types to respond to bioreductive compounds
combined with knowledge of the levels of various reductase
enzymes in these cell lines/tumours. It involves both the
rational design of compounds as targets for activation by
specific enzymes and enzyme profiling of both tumour tissue
and surrounding healthy tissue in order to define likely
targets for drug activation. For example, the levels of DT-
diaphorase have been shown to vary 10 000-fold in a panel of
23 tumour cell lines (Robertson et al., 1994) and also to be
elevated in tumour tissue compared with surrounding non-
cancerous tissue (Riley and Workman, 1992). The aerobic
toxicity of the indoloquinone E09 correlates highly with
intracellular DT-diaphorase activity (Plumb et al., 1994;
Robertson et al., 1994). Therefore, E09 should be targeted at
tumours with high levels of DT-diaphorase, and would be
expected to be of litle or no therapeutic benefit when used as
a single agent to treat tumours with low DT-diaphorase
levels. Knowledge of the substrate structure requirements of
DT-diaphorase should enable the rational design of
analogues of E09 for targeting at DT-diaphorase-rich
tumours. Another example of the 'enzyme-directed' ap-
proach is activation of the di-N-oxide bioreductive drug,
tirapazamine (SR 4233), in a panel of human breast cancer
cell lines (Patterson et al., 1995). Under hypoxic conditions
both the cytotoxicity of the drug and its conversion to a
deoxygenated product correlate with NADPH: cytochrome
P450 reductase activity.
The metabolic activation of the aromatic mono-N-oxide
bioreductive drug, RB90740, has been shown to be mediated,
at least in part, by cytochrome b5 reductase (Barham and
Stratford, 1996). However, in order to investigate the overall
importance of this enzyme in determining the cytotoxicity of
RB90740, it was necessary to develop an assay for
quantifying the level of enzyme in cell lines and tumours.
Methods reported in the literature do not appear to have
been validated, i.e. the non-dicoumarol-inhibitable reduction
of cytochrome c (Segura-Aguilar et al., 1990) or the NADH-
dependent reduction of cytochrome c (Plumb et al., 1994),
and assume that cytochrome b5 reductase is the only enzyme
responsible for the NADH-dependent reduction of cyto-
chrome c. Our data indicate that this assumption is not valid.
From Figure 4 it is evident that cytochrome b5 reductase
activity does not account for all of the NADH-dependent
reduction of cytochrome c in any cell line, as assessed using
pHMB as a selective inhibitor. Moreover, in some cell lines,
for example ZR75, the cytochrome b5 reductase activity
accounts for only 60% of the total reduction of cytochrome
c. This, therefore, suggests that the method of Plumb et al.
(1994) consistently overestimates cytochrome b5 reductase
activity, possibly by as much as 100%.
The method of Segura-Aguilar et al. (1990) also assumes
that dicoumarol is a selective inhibitor of DT-diaphorase. We
found that dicoumarol did not inhibit the NADH-dependent
reduction of cytochrome c catalysed by mouse liver
microsomes (data not shown). However, Hodnick and
Sartorelli (1993) have shown that dicoumarol inhibits the
reduction of mitomycin C by purified cytochrome b5
reductase by 24% and 57% at concentrations of 100 lM
and 300 iM respectively. The concentration of dicoumarol
used in the DT-diaphorase assay is 100 gM. Our data support
this latter finding. From Figure 3b it can be seen that the
dicoumarol non-inhibitable reduction of cytochrome c is an
underestimation of cytochrome b5 reductase activity, suggest-
ing that dicoumarol is inhibiting cytochrome b5 reductase to
some extent.
Thus, our data show that the method used by Segura-
Aguilar et al. (1990) will largely underestimate cytochrome b5
reductase activity, especially in cells with high DT-diaphorase
levels, whereas the method used by Plumb et al. (1994) will
overestimate b5 reductase activity to varying degrees. There-
fore, neither of these protocols can be considered to give
accurate assessments of enzyme activity. An alternative assay
involves using cytochrome b5 as the electron acceptor in place
of cytochrome c (Tamura et al., 1988; Guiray and Arinc,
1991). Teleologically speaking, this might be considered to be
a more suitable assay since cytochrome b5 is the natural
substrate for the reductase enzyme. However, cytochrome b5
is not available commercially and therefore would have to be
purified. This makes it far from ideal for a routine assay,
especially as it would be difficult to regulate the quality of the
purified cytochrome b5. Cytochrome c is available commer-
cially, is already used in a variety of reductase assays, and is
therefore an ideal alternative substrate.
The assay described here employing pHMB has been used
to measure the cytochrome b5 reductase activity of a panel of
human tumour cell lines in use in our laboratory for drug
evaluation and development. The enzyme activity varied 3-
fold when expressed per mg of protein, and 7-fold when
expressed per million cells. The latter takes into account the
fact that the cells differ in size, especially when small-cell lung
cancer cells are included in the panel, and therefore may be
considered to be a more accurate reflection of variability
between the lines than data expressed per mg of protein,
especially when making comparisons with estimates of the
cytotoxicity of a drug which are derived on a per cell basis.
NADPH: P450 reductase activity has been shown to vary
approximately 6-fold in the same panel of cell lines when
expressed per mg protein (Chinje et al., unpublished data),
whereas DT-diaphorase levels vary some 10 000-fold
(Robertson et al., 1994). Plumb et al. (1994) have also
reported values ofcytochrome b5 reductase activity in a panel
of human cell lines. Their data show an approximately 12-
fold range in activity, but with higher activities than reported
here. However, the assay they used was essentially the DT-
diaphorase assay, omitting menadione. Their assay incorpo-
rated BSA, which stimulates DT-diaphorase activity (Ernster
et al., 1962) and used Tris buffer rather than phosphate
buffer. We have found cytochrome b5 reductase activity is
similar in the two types of buffer and does not appear to be
stimulated by BSA (0.14%), at least in phosphate buffer (data
not shown). However, the enzyme activities measured by
Plumb et al. (1994) were the NADH-dependent reduction of
cytochrome c. We have shown here that this method
overestimates cytochrome b5 reductase activity, in some
cases by as much as 90-100%, depending on the presence
of other reductase enzymes. On this basis we feel that our
method is more fully validated, and gives a more accurate
reflection of intracellular cytochrome b5 reductase activities.
Spectrophotometric assays are used widely to measure the
activity of reductase enzymes. Ideally, the assay for
cytochrome b5 reductase described here should be validated
more fully using an immunological method. For example,
selective antibodies to cytochrome b5 reductase could be used
to inhibit the enzyme, and this level of inhibition comparedNADH: cytohmm b5 reduhtase acvity in tumour cels
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with that achieved by pHMB. However, such antibodies are
not currently available. Also. it must be considered that
antibodies are not always entirely selective. and. therefore.
may not give an accurate measure. An alternative approach
might be to compare the levels of cytochrome b5 reductase
protein. measured using Western blotting, uWith the reductase
activity measured using the cytochrome c assay. Unfortu-
nately. this method also requires antibodies to the enzyme.
and also assumes that all the protein is active. In the absence
of appropriate antibodies. the assay that we have described
here. measuring cytochrome b. reductase activity as the
pHMB-inhibitable reduction of cytochrome c. is suitable for
comparing levels of cytochrome b5 reductase in different
tumour cell lines. and is certainly more accurate than either
the dicoumarol non-inhibitable (Segura-Aguilar et al.. 1990)
or the NADH-dependent (Plumb et al.. 1994) reduction of
cytochrome c.
We have used the assay described here to measure a 7-fold
range in activity of cytochrome b5 reductase in a panel of 22
human tumour cell lines. This variation is far less than has
been demonstrated for the reductase DT-diaphorase. How-
ever, Patterson et al. (1995) have recently shown that the
activity of NADPH: cytochrome P450 reductase varies only
6-fold among a panel of human breast tumour cell lines. with
enzyme activity clearly correlating with both toxicity and
metabolism of the bioreductive drug. tirapazamine. Such an
analogy suggests that the variation in cytochrome b.
reductase activity between cell lines may be a highly
exploitable difference. This would be particularly so. if
measurements of tumour reductase activity were combined
with estimates of the level of hypoxia in the tumours.
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